Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scans reveal hidden effects of childhood cancer treatment

NCT ID NCT03208387

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study looks at how surviving a pediatric brain tumor affects thinking and behavior. Researchers will use brain scans to examine brain structure in children who have completed treatment. The goal is to better understand the long-term cognitive challenges these survivors may face.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify brain changes linked to cognitive problems in pediatric brain tumor survivors, guiding future support strategies.
What could go wrong
This is a small pilot study with only 42 participants, focused on feasibility. It may not produce definitive results or directly lead to treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

42 people

The number who actually took part.

Started

Jun 2017

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited at MSK and three participating sites (Columbia University, University of Washington and University of Texas Southwestern).

Ages

6 to 16 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Children Treated for Posterior Fossa Tumors: * As per medical record or clinical report, successfully completed all medical treatment for either an M0 posterior fossa medulloblastoma without dissemination or posterior fossa low-grade astrocytoma without relapse or evidence of residual disease. * For medulloblastoma survivors only: Previously treated with gross total resection (GTR), craniospinal irradiation with conformal posterior fossa boost radiotherapy (CSI + Boost) and chemotherapy * For low grade astrocytoma survivors only: Previously treated with gross total resection ONLY (no chemotherapy or radiotherapy). * As per medical record or clinician report, between 1-10 years post completion of their medical treatment for their posterior fossa brain tumor. * Subject is between the ages of 6 through 16 years at time of consent. * As per medical record or parent report, subject is able to tolerate an MRI without sedation. Healthy Control Participants: * No major medical illness, as determined by medical interview by study physician. * As per parent report, subject is between the ages of 6 through 16 years at time of consent. * As per parent report, subject is able to tolerate an MRI without sedation. Exclusion Criteria: All Participants: * Full Scale IQ as documented to be below a standard score of \<70 based upon the study IQ assessment completed after consent. * As per self or parent report, completed any portion of the neuropsychological battery used in this study within the last year. * MRI contraindications (e.g., implanted ferromagnetic devices, claustrophobia) as per radiology clinical operating procedures. * As per self or parent report or medical record, currently taking medications that have CNS effects (i.e., antidepressants, neuroleptics, anti-seizure medications, drugs that affect blood pressure or heart rate, alpha-agonists, adrenergic blockers, lithium, sedating antihistamines, and some medications for the treatment of asthma). * As per self or parent report, non-fluency in English language as demonstrated by current educational placement in a non-English-speaking classroom setting.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University

    New York, New York, 10032, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Seattle Children's Hospital

    Seattle, Washington, 98105, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.